RASA1 and cancer: Since mutationally activated RAS was first discovered in human cancer in 1982,382 mutations of RAS have been well established as the drivers of diverse types of lethal cancers, such as colorectal cancer, pancreatic cancer, and lung cancer.383–388 Oncogenic mutations of RAS usually disrupt the GAP-mediated GTP hydrolysis and lead to constitutive activation.